Development of Coronavirus Treatments Using Neutralizing Antibodies
The Coronavirus disease 2019 (COVID-19), caused by the novel coronavirus SARS-CoV-2, was first reported in December 2019 in Wuhan, Hubei province, China. This virus has led to 61.8 million cases worldwide being reported as of December 1st, 2020. Currently, there are no definite approved therapies en...
Main Authors: | Saman Fouladirad, Horacio Bach |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-01-01
|
Series: | Microorganisms |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-2607/9/1/165 |
Similar Items
-
Comparison and Analysis of Neutralizing Antibody Levels in Serum after Inoculating with SARS-CoV-2, MERS-CoV, or SARS-CoV Vaccines in Humans
by: Sicong Yu, et al.
Published: (2021-06-01) -
Highly pathogenic coronaviruses: thrusting vaccine development in the spotlight
by: Chunting He, et al.
Published: (2020-07-01) -
The interplay between emerging human coronavirus infections and autophagy
by: Zhenyu Zhao, et al.
Published: (2021-01-01) -
The relation between avian coronaviruses and SARS-CoV-2 coronavirus
by: Hanan Al-Khalaifah, et al.
Published: (2022-10-01) -
Chemokine Regulation During Epidemic Coronavirus Infection
by: Shamik Majumdar, et al.
Published: (2021-02-01)